WO1998014213A1 - Stabilisateur de la membrane mitochondriale - Google Patents
Stabilisateur de la membrane mitochondriale Download PDFInfo
- Publication number
- WO1998014213A1 WO1998014213A1 PCT/JP1997/003485 JP9703485W WO9814213A1 WO 1998014213 A1 WO1998014213 A1 WO 1998014213A1 JP 9703485 W JP9703485 W JP 9703485W WO 9814213 A1 WO9814213 A1 WO 9814213A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- mitochondrial
- carbon atoms
- oxo
- therapeutic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
Definitions
- the present invention relates to a preventive and / or therapeutic agent for a disease caused by a mitochondrial dysfunction or accompanied by a mitochondrial dysfunction.
- Intracellular calcium ion acts as an important messenger under physiological conditions, but is known to be a cytotoxic factor when it is increased above a certain concentration.
- excess glutamate causes calcium ions to flow into cells via its receptor (NMDA type) and induce neuronal necrosis (Choi,
- ATP is synthesized based on the high potential energy due to the active transport of this hydrogen ion (H + ) (kagawa, Y., Cell Engineering, 11, 3-11, 1992).
- mitochondrial membrane depolarization is caused by various external or internal factors, and that the depolarization may contribute to mitochondrial dysfunction.
- dysfunction of mitochondria has been observed in various diseases, and dysfunction of mitochondria is considered to be an important etiology in some diseases.
- ischemic diseases such as ischemic brain disease and ischemic heart disease, Parkinso
- mitochondrial diseases such as degenerative diseases caused by abnormal mitochondrial diseases such as Alzheimer's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and mitochondrial encephalomyopathy, and various toxicities caused by carbon monoxide and the like.
- ALS amyotrophic lateral sclerosis
- mitochondrial encephalomyopathy and various toxicities caused by carbon monoxide and the like.
- Abnormal function of the driller If a substance that protects the mitochondrial membrane from the action of various external or internal factors and stabilizes the mitochondrial membrane by maintaining a physiological membrane potential is provided, treatment of these diseases, It is expected to be extremely useful for prevention. Disclosure of the invention
- An object of the present invention is to protect the mitochondrial membrane from the action of various external or internal factors, and to stabilize the mitochondrial membrane by suppressing or eliminating the depolarization of the mitochondrial membrane. It is to provide a substance having: Another object of the present invention is to provide a substance having a function of stabilizing a mitochondrial membrane and preventing a mitochondrial dysfunction accompanying depolarization of the mitochondrial membrane. Still another object of the present invention is to provide a substance having the above-mentioned action as an active ingredient, and to prevent and / or treat a disease caused by a mitochondrial dysfunction or accompanied by a mitochondrial dysfunction. To provide an agent.
- the present inventors have made intensive efforts to solve the above problems, and as a result, for the first time, the existence of a substance having an action of stabilizing a mitochondrial membrane by suppressing or eliminating depolarization of the mitochondrial membrane. confirmed.
- the present inventors have further conducted studies to be able to protect the mitochondrial membrane from depolarization due to external or internal factors by stabilizing the mitochondrial membrane, and / or It has been found that the physiologically polarized state can be maintained or restored, and that the physiological energy production of mitochondria can be maintained or restored.
- a substance having such an action binds to the benzodiazepine receptor present on the mitochondrial membrane as an antagonist, thereby suppressing the action of agonist that destabilizes the mitochondrial membrane. I found what I could do.
- the present invention has been completed based on these findings.
- the present invention effectively uses a substance having a stabilizing action on mitochondrial membrane. It is intended to provide a preventive and / or therapeutic agent for a disease which is contained as a component, is caused by a mitochondrial dysfunction, or is accompanied by a mitochondrial dysfunction.
- the above-mentioned prophylactic and / or therapeutic agent wherein the stabilizing action on the mitochondrial membrane is an action of suppressing or eliminating depolarization of the mitochondrial membrane;
- the above preventive and / or therapeutic agent caused by an increase in intracellular calcium ion concentration; a stabilizing effect on mitochondrial membrane;
- the above-mentioned prophylactic and / or therapeutic agent which has an action of maintaining or recovering the disease, and the above-mentioned prophylactic and / or therapeutic agent, wherein the disease is selected from the group consisting of ischemic disease, toxicosis, and degenerative disease.
- the present invention also provides the above prophylactic and / or therapeutic agent, wherein the substance is a mitochondrial benzodiazepine receptor antagonist.
- the above prophylactic and / or therapeutic agent wherein the ischemic disease is ischemic disorder of the cerebral nervous system or cerebrovascular system, ischemic heart disease, renal failure, or hepatic failure; Abnormal mitochondrial enzyme activity, mitochondrial gene mutation, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), mitochondrial encephalomyopathy, or the above-mentioned prophylaxis with Zyman-Pick disease and Z or Therapeutic agent; and the above-mentioned prophylactic and / or therapeutic agent, wherein the poisoning is gas poisoning, alcohol poisoning, drug poisoning, pesticide poisoning, heavy metal poisoning, or poisoning due to natural animal or plant toxins. .
- the present invention provides a method for administering an effective amount of a substance having an action of stabilizing a mitochondrial membrane to a mammal including a human, which is caused by abnormal mitochondrial function,
- the present invention provides a method for preventing and / or treating a disease associated with abnormal doria function.
- the present invention provides a mitochondrial membrane stabilizer containing mitochondrial benzodiazepine receptor as an active ingredient; and a mitochondrial benzodiazepine receptor.
- a preventive and / or therapeutic agent for diseases caused by or accompanied by mitochondrial dysfunction which comprises antagonist as an active ingredient.
- FIG. 1 shows the effect of Ro5-4864 on intracellular Ca 2+ concentration.
- FIG. 2 shows the effect of Ro5-4864 on mitochondrial membrane potential.
- FIG. 3 is a graph showing the effect of Ro5-4864 on intracellular Ca 0+ concentration in NG108-15 neurons treated with bradykinin and finfin.
- FIG. 4 is a graph showing the effect of Ro5-4864 on mitochondrial membrane potential in NG108-15 neurons treated with bradykinin and caffeine.
- FIG. 5 is a diagram showing that the medicament of the present invention (nefiracetam) inhibits an increase in intracellular Ca 2+ concentration caused by Ro5-4864.
- FIG. 6 is a diagram showing that the medicament of the present invention (nefiracetam) inhibits the depolarizing effect of Ro5-4864 on mitochondrial membrane.
- FIG. 7 shows that the medicament of the present invention (PK11195) inhibits the depolarizing effect of Ro5-4864 on mitochondrial membranes and activates mitochondrial benzodiazepine receptor (MBR).
- FIG. 4 is a diagram showing the results of the interlocking of mitochondrial membrane depolarization with intracellular Ca + concentration.
- FIG. 8 shows that the drug of the present invention (PK11195) inhibits the effect of Ro5-4864 on mitochondrial membrane potential, and that the drug of the present invention and Ro5-4864 compete for MBR.
- FIG. 9 is a diagram showing a result that is acting as a target.
- FIG. 9 is a graph showing the effect of Ro5-4864 on intracellular Ca 2T concentration in cells treated with the medicament of the present invention (NCS-1044-90).
- FIG. 10 is a graph showing the effect of Ro5-4864 on the intracellular mitochondrial membrane potential in cells treated with NCS-1044-90.
- the drug of the present invention acts on the mitochondrial membrane to stabilize the membrane (particularly the inner membrane).
- the medicament of the present invention may contain various external factors (such as exposure to toxic substances) or internal factors (such as abnormal expression of genes, etc.) Protects the mitochondrial membrane from depolarization caused by abnormalities, etc., and maintains or restores the physiologically polarized state of the mitochondrial membrane to maintain or restore physiological energy production in the mitochondria.
- abnormality of mitochondrial function refers to substantially any abnormality in mitochondrial function, including the above-mentioned decrease in energy production capacity (functional decline). Is used as a concept that includes all of the cases where
- physiological as used herein means that the cells are in a state substantially the same as the average intracellular environment in which normal life activity is maintained.
- the medicament of the present invention has an effect of stabilizing the mitochondrial membrane, particularly when the intracellular calcium ion concentration is increased, and substantially completely suppresses the depolarization of the membrane. It suppresses depolarization and maintains or restores the mitochondrial ATP-producing ability to a physiological state.
- the medicament of the present invention is capable of binding to, and binding to, mitochondrial benzodiazepine receptor (MBR).
- MBR mitochondrial benzodiazepine receptor
- MBR agonist that destabilizes the mitochondrial membrane potential [eg 7-chloro-5- (4-chlorophenyl) -1,3-dihydro-1-methyl- 2H-1,4-benzodiazepin-2-one : TIPS, December, pp. 506-511, 1986], acting as a competitive antagonist. It is considered that the medicament of the present invention stabilizes the mitochondrial membrane by antagonist action on MBR and exerts the above-mentioned physiological action.
- the medicament of the present invention is characterized by (a) the action of stabilizing the mitochondrial membrane, and (b) the action of stabilizing the mitochondrial membrane by an external factor or an internal factor. And / or (c) maintaining or restoring the physiologically polarized state of the mitochondrial membrane to maintain or restore the physiological production of mitochondrial energy. It is characterized by having. Therefore, the medicament of the present invention is not limited to a substance having a specific chemical structure. It is to be understood that any medicament containing a substance with characteristics is included in the scope of the present invention. The means for confirming the physiological characteristics described above is described in detail in the examples of the present specification.
- the medicament of the present invention contains a mitochondrial benzodiazepine receptor-antagonist as an active ingredient, and stabilizes a mitochondrial membrane, thereby causing a mitochondrial dysfunction, or Prevention and / or treatment of a disease associated with abnormal function of tochondria can be effectively achieved.
- Means for confirming the action as a mitochondrial benzodiazepine receptor.antagonist are also specifically described in the examples of the present specification.
- ischemic diseases resulting from or associated with mitochondrial dysfunction include, for example, ischemic diseases of organs such as liver, heart, brain, or kidney, and vasculature that governs them.
- ischemic disorders of the cerebral nervous system such as vascular cerebral disorders accompanied by one or more of symptoms such as sensory, motor disorders, speech disorders, memory disorders, dementia, seizures, and mental disorders; Ischemic heart disease; ischemic kidney injury such as renal failure; ischemic liver injury such as liver failure is a typical disease.
- These disorders include those caused by hypotension, hypoxia, and drug addiction.
- Examples of other diseases include degenerative diseases caused by mitochondrial abnormalities such as mitochondrial enzyme abnormalities and mitochondrial gene mutations (Shigenaga et al., Pro Natl. Acad. Sci., USA, 91, 10771-10778, 1994; Tanaka , M., et al., Internal Medicine, 77, 88 887, 1996), and various toxicosis.
- Degenerative diseases that have been proven or suggested to be involved in mitochondrial dysfunction include Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and mitochondrial encephalomyopathy (Ohnishi, H. et al. , Cranial nerves, 44, 259-264, 1992), Niemann's disease, and the like.
- Examples of poisoning include gas poisoning with carbon monoxide gas, carbon dioxide gas, cyanide gas, alcohol poisoning, drug poisoning, pesticide poisoning with pyrethroid pesticides and organophosphorus pesticides, heavy metal poisoning, or puffer fish Poisoning caused by toxins of natural animals and plants, such as poisons and mushroom venoms.
- R represents a hydrogen atom or a hydroxyl group
- R 1 represents a hydrogen atom or a methyl group
- R 2 represents a pyridyl group or a substituted phenyl group substituted with one to three same or different substituents.
- substituent on the phenyl group include a halogen atom (in the present specification, a “halogen atom” may be any of a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom), and a trifluoromethyl group.
- substituent of the fuunyl group include a halogen atom such as a chlorine atom or a fluorine atom; an alkyl group such as a methyl group, an ethyl group, an n-propyl group, a sec-butyl group, or an n-butyl group; An alkyl mercapto group such as a methyl mercapto group, an n-propylmethylcapto group, an isopropylmercapto group, a sec-butylmercapto group, or an n-heptylmercapto group; 2-hydroxypropylmercapto group; A substituted alkylmercapto group such as a 2- (N, N-dimethylamino) -propylmercapto group or a 2- (N-methyl-N-benzylamino) -ethylmercapto group; a general formula: -S- (CH 0 ) -CH (R 3 ) -
- the unsubstituted pyridyl group represented by R 2 can be suitably used, and any of a 2-pyridyl group, a 3-pyridyl group, and a 4-pyridyl group may be used.
- a compound group suitable as an active ingredient of the medicament of the present invention
- particularly preferred compounds are 2-oxo-1-pyrrolidinylacetic acid 2,6-dimethylanilide [ ⁇ - (2,6-dimethylphenyl) -2- ( 2-oxo- 1-pyrrolidinyl) acetamide, generic name: nephiracetam]; 2-pyrrolidone-acetamide; trianisyl-2-pyrrolidinone; and 4-hydroxy-2-oxo-1 -Pyrrolidine acetate.
- R 11 and!? 12 are each independently a linear or branched alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 7 carbon atoms, A phenylalkyl or cycloalkyl-substituted alkyl group having 1 to 3 atoms, or an alkenyl or alkynyl group having 3 to 6 carbon atoms (however, a double bond or a triple bond is A and B each independently represent N or CH; X 1 and X 2 each independently represent a halogen atom, a straight-chain or branched-chain having 1 to 3 carbon atoms.
- Ar represents an alkyl group, a linear or branched alkoxy group having 1 to 3 carbon atoms, a nitro group, or a trifluoromethyl group;
- Ar represents a phenyl group, a pyridyl group, a phenyl group, or a substituted phenyl group;
- Substituents on the phenyl group include a halogen atom, a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkoxy group having 1 to 4 carbon atoms, And one or two substituents selected from the group consisting of a linear or branched alkylthio group having 4 carbon atoms, a trifluoromethyl group, and a nitro group.
- X 1 and X 2 are hydrogen atoms
- Ar is a substituted phenyl group
- B is CH
- A is N
- R 11 and R 12 are each independently Compounds which are straight-chain or branched-chain alkyl groups having up to 6 carbon atoms are preferred.
- X 1 and X 2 are hydrogen atoms
- Ar is a cyclophenyl group
- B is CH
- A is ⁇
- R 11 is a methyl group
- R 12 is 1 to Compounds which are linear or branched alkyl groups having 6 carbon atoms can be mentioned.
- Particularly preferred compounds are N-methyl-N- (1-methylpropyl)-(2-chlorophenyl) isoquinolin-3-carboxamide, and optically active forms thereof.
- R 21 represents an unsubstituted phenyl group, a substituted phenyl group (substituents on the phenyl group are a halogen atom, a linear or branched alkyl group having 1 to 6 carbon atoms, and 1 to 6 Represents one or two substituents selected from the group consisting of a straight-chain or branched-chain alkoxy group having the same carbon atom) or a cesyl group; 1 ⁇ 2 represents a hydrogen atom or a halogen atom A linear or branched alkyl group having 1 to 6 carbon atoms which may have a substituent (substituents are selected from an amino group, an alkylamino group, and a dialkylamino group).
- R 23 is a group represented by (R 24 ) (R 25 ) N-CO-Q- (wherein Q is a linear or branched alkylene group having 1 to 6 carbon atoms; 24 and R 23 each independently represent a linear or branched alkyl group having 1 to 6 carbon atoms, unsubstituted phenyl Or a substituted phenyl group (substituents on the phenyl group may be halogen atoms,
- X 3 represents a hydrogen atom or a halogen atom
- Y represents an oxygen atom or a sulfur atom.
- R 21 is a substituted phenyl group (the substituent on the phenyl group is a halogen atom, a linear or branched alkyl group having 1 to 6 carbon atoms)
- R 22 is a halogen atom; and R 22 is a halogen atom; and
- R 2 is a substituent selected from the group consisting of a straight-chain or branched-chain alkoxy group having 1 to 6 carbon atoms.
- R 24 is (R 24) (R 25) N - C0-Q- in group (wherein represented, Q is a linear or branched alkylene group having 1 to 6 carbon atoms, R 24 Is a linear or branched alkyl group having 1 to 6 carbon atoms, and R 25 is an unsubstituted phenyl group or a substituted phenyl group (substituents on the phenyl group are halogen atoms, 1 to 6 One or two substituents selected from the group consisting of a straight-chain or branched-chain alkyl group having 2 carbon atoms, and a straight-chain or branched-chain alkoxy group having 1 to 6 carbon atoms.
- X 3 is hydrogen atom;
- Y compound is an oxygen atom is preferred also, R 1 is located at Kurorofuweniru group 1 ⁇ 2 is bromine atom;
- R 23 is (R 24) (R 23) N- CO- Q- group represented by (wherein, Q represents a straight-chain or branched having 1 to 6 carbon atoms A chain alkylene group, R 24 is a linear or branched alkyl group having 1 to 6 carbon atoms, R 25 is an unsubstituted phenyl group;
- X 3 is a hydrogen atom;
- Y is Compounds that are oxygen atoms are more preferred.
- a particularly preferred compound is 2_ (3-chlorophenyl) -3-promo-6- (N-methyl-N-phenylacetamide) -5-oxo-5,6-dihydromidazo [1,2-c] quinazoline Can be mentioned.
- This compound is described as the 42nd compound in the examples of JP-A-4-2177682.
- JP-A-56-2960, JP-A-61-280470, JP-A-4-160496, JP-A-58-201756, -It can be easily manufactured according to the method described in Japanese Patent No. 217682.
- the pyrrolidinyl acetate amide derivative disclosed in Japanese Patent Publication No. 3-46466 has an effect of improving brain function (Japanese Patent Publication No. 62-5404) and an effect of improving Alzheimer-type dementia (Japanese Patent Application Laid-Open No. 5-163144). Amelioration of cerebral vascular dementia (Japanese Patent Application Laid-Open No.
- physiologically acceptable salts include mineral salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, and phosphate, or acetate, maleic acid, and the like. Salt, fumarate, citrate, oxalate, succinate, tartrate, lignate, mandelic, methanesulfonate, P-toluenesulfonate, 10-camphorsulfonate, etc. And acid addition salts such as organic acid salts.
- each asymmetric carbon is not particularly limited, and any optically active isomer or optical isomer may be used. Any mixture or racemate may be used. Also, any mixture of diastereoisomers based on two or more asymmetric carbons may be used.
- the administration form of the medicament of the present invention is not particularly limited, and can be administered orally or parenterally.
- a compound which is an active ingredient for example, a compound of the above formula (I) may be used as it is, but a compound of the active ingredient and a pharmacologically and pharmaceutically acceptable additive for a pharmaceutical are used.
- compositions comprising Pharmaceutically and pharmaceutically acceptable additives include, for example, excipients, disintegrants or disintegration aids, binders, lubricants, coating agents, pigments, diluents, bases, A solubilizer or a solubilizing agent, a tonicity agent, a pH adjuster, a stabilizer, a propellant, an adhesive, or the like can be used.
- formulations suitable for oral administration include, for example, tablets, capsules, powders, fine granules, granules, solutions, syrups, and the like.
- Formulations suitable for parenteral administration include, for example, injections, drops, suppositories, inhalants, patches, and the like. It should be noted that the medicament of the present invention may contain one or more active ingredients.
- the dose of the medicament of the present invention is not particularly limited, and an appropriate dose can be selected according to various conditions such as the purpose of treatment or prevention, the type of disease, the age and symptoms of the patient, and the administration route. is there.
- about 10 mg to l It is about 000 mg, preferably about 60 mg to 900 mg.
- the acute toxicity of 2, oxo-1-pyrrolidinylacetic acid 2,6-dimethylanilide [generic name: nefiracetam], which is particularly preferably used in the present invention, is 2,005 mg / kg (male mouse, ⁇ ⁇ ⁇ ⁇ ), which has proven to be highly safe (Japanese Patent Laid-Open No. 5-163144).
- Fluorescent reagent f ura2- AM [1- [6- Amino- 2- (5- carboxy-2- oxazolyl)-5-benzofuranyloxy] -2- (2-amino-5-methylphenox ⁇ -ethane-N, N, ⁇ ', N' -tetraacetic acid, pentaacetoxymethyl ester, manufactured by Dojin-Danigaku Kenkyusho]
- the intracellular Ca 2+ concentration was measured in a Petri dish in which NG108-15 cells were cultured. After removing the culture solution, wash twice with HBS, add the 5 nt fura2-AM solution prepared above to the cultured cells, leave the mixture in a carbon dioxide incubator for 30 minutes, and then add the added fura2- Washed 5 times with HBS to remove AM solution. Finally, 1 ml of HBS was added to Flexi Palm, and the intracellular Ca 2+ concentration was measured using ARGUS-50 / CA (manufactured by Hamamatsu Photonics).
- Rhodamine 123 (2- [6-Amino-3-imino-3H-xanthen-9-yl] -benzoicacid methylester, manufactured by Sigma) was dissolved and diluted with HBS to prepare a solution having a final concentration of 10 M.
- the culture solution of NG108-cells cultured in the Petri dish was removed, and the cells were washed twice with HBS.
- the Rhodamine 123 solution was stirred again, it was added to the cultured cells, and the cells were allowed to stand in a carbon dioxide incubator for 10 minutes. Then, the plate was washed five times with HBS to remove the added rhodamine 123 solution.
- HBS (1 ml) was added to a flexi palm disk containing the cells, and the mixture was again left still in a carbon dioxide incubator for 10 minutes. Finally, the cells were washed once with HBS and used for the experiment.
- ARGUS-50 / CA (manufactured by Hamamatsu Photonics) was used for measuring intracellular Ca 2+ concentration.
- Ro5-4864 50 / M was added to cultured NG108-15 neurons, and the potential change was subsequently measured with ARGUS-50 / CA over time. From the results shown in Fig. 2, it was found that the addition of Ro5-4864 markedly reduced the mitochondrial membrane potential and caused depolarization of the membrane.
- FIG. 3 is a graph showing the effect of Ro5-4864 on intracellular Ca 2+ concentration in cells in which NG108-neural cells were treated with bradykinin and force fin.
- Ro5--4864 (50) significantly increased intracellular Ca 2T concentration. Bradykinin does not act on mitochondria, another storage site for intracellular Ca 2+ Therefore, it was shown that the increase in intracellular Ca 2+ concentration due to Ro5-4864 was caused by mitochondria.
- Mitochondrial membrane potential was measured in the same manner as in Example 2. No change was observed in the mitochondrial membrane potential when caffeine (10 ⁇ ) or bradykinin ( ⁇ ⁇ ⁇ ) was applied, but the marked mitochondrial membrane was observed when Ro5--4864 (50 ⁇ M) was applied. A decrease in the potential was observed, confirming that the mitochondrial membrane was depolarized (Fig. 4).
- Example 4 Nefuirasetamu treatment on intracellular Ca 2+ concentration in cells Ro5- 4864 Effect of RO5 - 4864 by applying (25 M) was confirmed an increase in the intracellular Ca 2+ concentration (Figure 5: the first peak ).
- Example 5 The effect of the medicament of the present invention on the mitochondrial membrane potential of mitochondrial membrane potential in nephrasetam-treated cells was examined in the same manner as in Example 2.
- N-Methyl- - ⁇ -methylpropyl)-(2-chlorophenyl) isoquinolin-3-carboxamide (PK11195, racemic form) was produced in the same manner as described above. .. mp 133- 134 ° C ( CHClg-EtOH), Anal Calcd for C 21 H 21 ClN o 0 2 C, 71. 48%; H, 6. 00%; N, 7. 943 ⁇ 4 Found C, 71. 19 %; H, 5.94 3 ⁇ 4; N, 8.06%
- Ro5-4864 (50 / M) was applied to confirm an increase in intracellular Ca 2+ concentration (FIG. 7: first peak). Then, after pre-treatment with PK11195 (20 M), Ro5-4864 was applied. The effect of increasing the Ca 2+ concentration was suppressed. This result indicates that the activation of the MBR (mitochondrial benzodiazepine receptor) by PK11195 links the mitochondrial membrane depolarization with the intracellular Ca 2+ concentration. .
- Example 7 Effect of Ro5-4864 on mitochondrial membrane potential in PK11195-treated cells The effect of the drug of the present invention on mitochondrial membrane potential was examined in the same manner as in Example 2. When PK11195 (20 / M) was first applied, no change was observed in the mitochondrial membrane potential.
- the drug of the present invention has a function of stabilizing the mitochondrial membrane and preventing mitochondrial dysfunction caused by destabilization of the mitochondrial membrane such as depolarization of the mitochondrial membrane. It is useful as an active ingredient of a prophylactic and / or therapeutic agent for diseases such as ischemic disease and toxicosis caused by dysfunction or accompanied by dysfunction of mitochondria.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/269,208 US6417220B2 (en) | 1996-10-01 | 1997-09-30 | Mitochondrial membrane stabilizer |
AU43230/97A AU727482B2 (en) | 1996-10-01 | 1997-09-30 | Mitochondrial membrane stabilizer |
EP97941283A EP0953356A4 (en) | 1996-10-01 | 1997-09-30 | MITOCHONDRIAL MEMBRANE STABILIZER |
CA002267375A CA2267375A1 (en) | 1996-10-01 | 1997-09-30 | Mitochondrial membrane stabilizer |
NO991570A NO991570L (no) | 1996-10-01 | 1999-03-30 | Mitokondriell membranstabilisator |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP26064996 | 1996-10-01 | ||
JP8/260649 | 1996-10-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998014213A1 true WO1998014213A1 (fr) | 1998-04-09 |
Family
ID=17350858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/003485 WO1998014213A1 (fr) | 1996-10-01 | 1997-09-30 | Stabilisateur de la membrane mitochondriale |
Country Status (8)
Country | Link |
---|---|
US (1) | US6417220B2 (ja) |
EP (1) | EP0953356A4 (ja) |
KR (1) | KR20000048847A (ja) |
CN (1) | CN1239437A (ja) |
AU (1) | AU727482B2 (ja) |
CA (1) | CA2267375A1 (ja) |
NO (1) | NO991570L (ja) |
WO (1) | WO1998014213A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999058117A1 (fr) * | 1998-05-13 | 1999-11-18 | Sanofi-Synthelabo | Utilisation de composes reduisant l'apoptose |
FR2778564A1 (fr) * | 1998-05-13 | 1999-11-19 | Sanofi Sa | Utilisation de composes reduisant l'apoptose |
US6399650B2 (en) | 2000-02-23 | 2002-06-04 | Daiichi Pharmaceutical Co., Ltd. | Method for improving disturbancies of activities of daily living after stroke |
WO2005040135A1 (ja) * | 2003-10-24 | 2005-05-06 | Ono Pharmaceutical Co., Ltd. | 抗ストレス薬およびその医薬用途 |
US7608636B2 (en) | 2000-12-28 | 2009-10-27 | Hamilton Pharmaceuticals, Inc. | Medicines for treatment and prevention of neurogenic pain |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040077709A1 (en) * | 1999-05-31 | 2004-04-22 | Daiichi Pharmaceutical Co., Ltd. | Neuronal death inhibitors |
JP2003519794A (ja) * | 2000-01-14 | 2003-06-24 | マイトコー | 末梢性ベンゾジアゼピンレセプター結合因子の同定 |
US20060241144A1 (en) * | 2005-04-20 | 2006-10-26 | Albert Cha | Method for treating apathy syndrome |
KR101304772B1 (ko) * | 2011-04-11 | 2013-09-05 | 인제대학교 산학협력단 | NecroX―5를 유효성분으로 포함하는 미토콘드리아 기능 조절용 조성물 |
WO2014150318A1 (en) * | 2013-03-15 | 2014-09-25 | Mitochondrial Concepts Llc | Therapeutic agent for enhancing mitochondrial function |
WO2016100379A1 (en) * | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Anti-arrhythmicity agents |
KR102696318B1 (ko) * | 2021-04-23 | 2024-08-20 | 주식회사 알트메디칼 | 이소퀴놀린 유도체 화합물을 유효성분으로 포함하는 미토콘드리아 기능이상으로 인한 질환의 예방 또는 치료용 조성물 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02256617A (ja) * | 1989-03-30 | 1990-10-17 | Asahi Chem Ind Co Ltd | 脳細胞機能障害改善剤 |
WO1995019170A1 (fr) * | 1994-01-12 | 1995-07-20 | Rhone-Poulenc Rorer S.A. | Application du riluzole dans le traitement des maladies mitochondriales |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2923975A1 (de) | 1979-06-13 | 1980-12-18 | Nattermann A & Cie | Pyrrolidinone, verfahren zu deren herstellung und diese enthaltende arzneimittel |
IT1141287B (it) * | 1979-06-13 | 1986-10-01 | Nattermann A & Cie | Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono |
US4385053A (en) | 1981-03-11 | 1983-05-24 | Barry Reisberg | Treatment for human memory impairment associated with aging |
FR2525595A1 (fr) | 1982-04-27 | 1983-10-28 | Pharmuka Lab | Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments |
JPS625404A (ja) | 1985-07-01 | 1987-01-12 | Shinko Electric Co Ltd | 信号レベル変換装置 |
JPH0779442B2 (ja) | 1989-07-14 | 1995-08-23 | 日本テレビ放送網株式会社 | 雑音減少回路 |
FR2659329B1 (fr) | 1990-03-09 | 1994-06-03 | Adir | Nouveaux derives d'imidazo [1,2-c] quinazoline, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
JPH04160496A (ja) | 1990-10-23 | 1992-06-03 | Sharp Corp | 自動販売機の物品搬出機構 |
SK279285B6 (sk) * | 1991-05-02 | 1998-09-09 | Daiichi Pharmaceutical Co. | Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin |
ZA923134B (en) | 1991-05-02 | 1993-01-27 | Daiichi Seiyaku Co | Agent for improving dementia |
JP3388778B2 (ja) | 1991-05-02 | 2003-03-24 | 第一製薬株式会社 | 脳血管性痴呆改善剤 |
US6107330A (en) * | 1995-08-07 | 2000-08-22 | Daiichi Pharmaceutical Co., Ltd. | Inhibitor for narcotic analgesic dependence/resistance acquisition |
-
1997
- 1997-09-30 KR KR1019990702847A patent/KR20000048847A/ko not_active Application Discontinuation
- 1997-09-30 US US09/269,208 patent/US6417220B2/en not_active Expired - Fee Related
- 1997-09-30 WO PCT/JP1997/003485 patent/WO1998014213A1/ja not_active Application Discontinuation
- 1997-09-30 CA CA002267375A patent/CA2267375A1/en not_active Abandoned
- 1997-09-30 EP EP97941283A patent/EP0953356A4/en not_active Withdrawn
- 1997-09-30 CN CN97180240A patent/CN1239437A/zh active Pending
- 1997-09-30 AU AU43230/97A patent/AU727482B2/en not_active Ceased
-
1999
- 1999-03-30 NO NO991570A patent/NO991570L/no not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02256617A (ja) * | 1989-03-30 | 1990-10-17 | Asahi Chem Ind Co Ltd | 脳細胞機能障害改善剤 |
WO1995019170A1 (fr) * | 1994-01-12 | 1995-07-20 | Rhone-Poulenc Rorer S.A. | Application du riluzole dans le traitement des maladies mitochondriales |
Non-Patent Citations (1)
Title |
---|
See also references of EP0953356A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999058117A1 (fr) * | 1998-05-13 | 1999-11-18 | Sanofi-Synthelabo | Utilisation de composes reduisant l'apoptose |
FR2778564A1 (fr) * | 1998-05-13 | 1999-11-19 | Sanofi Sa | Utilisation de composes reduisant l'apoptose |
US6399650B2 (en) | 2000-02-23 | 2002-06-04 | Daiichi Pharmaceutical Co., Ltd. | Method for improving disturbancies of activities of daily living after stroke |
US7608636B2 (en) | 2000-12-28 | 2009-10-27 | Hamilton Pharmaceuticals, Inc. | Medicines for treatment and prevention of neurogenic pain |
WO2005040135A1 (ja) * | 2003-10-24 | 2005-05-06 | Ono Pharmaceutical Co., Ltd. | 抗ストレス薬およびその医薬用途 |
Also Published As
Publication number | Publication date |
---|---|
NO991570L (no) | 1999-05-28 |
EP0953356A4 (en) | 2002-04-17 |
AU4323097A (en) | 1998-04-24 |
EP0953356A1 (en) | 1999-11-03 |
US6417220B2 (en) | 2002-07-09 |
CN1239437A (zh) | 1999-12-22 |
AU727482B2 (en) | 2000-12-14 |
US20010051641A1 (en) | 2001-12-13 |
NO991570D0 (no) | 1999-03-30 |
KR20000048847A (ko) | 2000-07-25 |
CA2267375A1 (en) | 1998-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006212772B2 (en) | Combination of organic compounds | |
US4988710A (en) | Aryl-cycloalkyl-alkanolamines for treatment of cholinergic neurotoxins | |
KR101277520B1 (ko) | (할로벤질옥시)벤질아미노-프로판아미드를 포함하는 선택적 나트륨 및/또는 칼슘 채널 조절제로서 유용한 약제학적 조성물 | |
WO1998014213A1 (fr) | Stabilisateur de la membrane mitochondriale | |
KR20080067628A (ko) | 신경보호를 위한 소분자 화합물의 사용 방법 | |
US20080261958A1 (en) | Combination of Organic Compounds | |
SK2262002A3 (en) | Composition comprising a tramadol material and an anticonvulsant drug | |
Klusa | Atypical 1, 4-dihydropyridine derivatives, an approach to neuroprotection and memory enhancement | |
EP2681209B1 (en) | Compounds and methods for the treatment of pain and other disorders | |
LT3918B (en) | 2,4- and 2,5- substituted pyridin-n-oxides, methods for the production thereof, pharmaceutical compositions and preparation the same | |
JP2017519020A (ja) | コハク酸脱水素酵素阻害剤(SDHi’s) | |
US20200299268A1 (en) | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use | |
EP2382206B1 (en) | Compounds and methods for the treatment of pain and other diseases | |
Taya et al. | Nimodipine improves the disruption of spatial cognition induced by cerebral ischemia | |
SK18312000A3 (sk) | Aza-heterocyklické zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie | |
US5049555A (en) | Antagonists of specific excitatory amino acid receptors as neuroprotectants and anxiolytics | |
EP0110224A2 (de) | Benzoylthioverbindungen, ihre Herstellung und Verwendung als Arzneimittel | |
FI105025B (fi) | Menetelmä valmistaa (S)-alfa-fenyyli-2-pyridiinietaaniamiinia | |
US6451761B1 (en) | N′N′-dichlorinated omega-amino acids and uses thereof | |
PT1338604E (pt) | Trímeros de n-alquilglicina com a capacidade de proteger os neurónios contra as agressões excitotóxicas e composições contendo os ditos trímeros | |
TW201702253A (zh) | 磷酸肌酸類似物前藥、其組成物及用途 | |
US20130053411A1 (en) | Pharmaceutical composition and method for treating hypertension | |
US20110230452A1 (en) | Compounds and methods for the treatment of pain and other diseases | |
DE69931814T2 (de) | Umwandlung von cox-inhibierenden, nicht cox-2 selektiven inhibitoren in derivate von cox-2 selektiven inhibitoren | |
JP3023987B2 (ja) | (S)−α−フェニル−2−ピリジンエタンアミン(S)−マレートおよび医薬としてのその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97180240.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HU ID IL IS JP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2267375 Country of ref document: CA Ref document number: 2267375 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997002847 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997941283 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09269208 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1997941283 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997002847 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997941283 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019997002847 Country of ref document: KR |